fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 41. More products

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Sitagliptin & metformin

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Apo-Sitagliptin/Metformin XR · DIN 02506270 · 50 mg & 500 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin/Metformin XR · DIN 02506270 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN/METFORMIN XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Sitagliptin/Metformin XR: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8893). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02506270)

Source record
DIN 02506270: Apo-Sitagliptin/Metformin XR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002061; group id 757; item number 1858; lccId None; manufacturer id APX Source form: ER Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8893; ministry $0.8893 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02506270 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99561 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Janumet XR · DIN 02416786 · $0.8893 Sandoz Sitagliptin-Metformin XR · DIN 02529106 · $0.8893
Shortage status: active shortage (reported September 1, 2026, estimated to end October 16, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02506270
Shortage record checked October 6, 2026

Apo-Sitagliptin/Metformin XR · DIN 02506289 · 50 mg & 1000 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin/Metformin XR · DIN 02506289 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN/METFORMIN XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Sitagliptin/Metformin XR: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8893). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02506289)

Source record
DIN 02506289: Apo-Sitagliptin/Metformin XR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002051; group id 757; item number 1857; lccId None; manufacturer id APX Source form: ER Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8893; ministry $0.8893 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02506289 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99562 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Janumet XR · DIN 02416794 · $0.8893 Sandoz Sitagliptin-Metformin XR · DIN 02529114 · $0.8893
Shortage status: resolved shortage (ended October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02506289
Shortage record checked October 6, 2026

Janumet XR · DIN 02416786 · 50 mg & 500 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Janumet XR · DIN 02416786 Manufacturer: Merck Canada Inc.; listing date 2016-12-22 Health Canada: Marketed since 2015-01-13 · brand JANUMET XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416786)

Source record
DIN 02416786: Janumet XR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002061; group id 757; item number 1858; lccId None; manufacturer id MEK Source form: ER Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.8496; ministry $0.8893 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416786 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90139 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506270 · $0.8893 Sandoz Sitagliptin-Metformin XR · DIN 02529106 · $0.8893
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416786
Shortage record checked October 6, 2026

Janumet XR · DIN 02416794 · 50 mg & 1000 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Janumet XR · DIN 02416794 Manufacturer: Merck Canada Inc.; listing date 2014-10-29 Health Canada: Marketed since 2014-01-15 · brand JANUMET XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416794)

Source record
DIN 02416794: Janumet XR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002051; group id 757; item number 1857; lccId None; manufacturer id MEK Source form: ER Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.8496; ministry $0.8893 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416794 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90140 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506289 · $0.8893 Sandoz Sitagliptin-Metformin XR · DIN 02529114 · $0.8893
Shortage status: resolved shortage (ended September 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416794
Shortage record checked October 6, 2026

Sandoz Sitagliptin-Metformin XR · DIN 02529106 · 50 mg & 500 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Sitagliptin-Metformin XR · DIN 02529106 Manufacturer: Sandoz Canada Inc.; listing date 2023-04-28 Health Canada: Marketed since 2023-03-22 · brand SANDOZ SITAGLIPTIN-METFORMIN XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Sitagliptin-Metformin XR: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8893). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529106)

Source record
DIN 02529106: Sandoz Sitagliptin-Metformin XR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002061; group id 757; item number 1858; lccId None; manufacturer id SDZ Source form: ER Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8893; ministry $0.8893 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529106 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101829 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506270 · $0.8893 Janumet XR · DIN 02416786 · $0.8893
Shortage status: resolved shortage (ended October 3, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529106
Shortage record checked October 6, 2026

Sandoz Sitagliptin-Metformin XR · DIN 02529114 · 50 mg & 1000 mg · extended release tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Sitagliptin-Metformin XR · DIN 02529114 Manufacturer: Sandoz Canada Inc.; listing date 2023-04-28 Health Canada: Marketed since 2023-03-22 · brand SANDOZ SITAGLIPTIN-METFORMIN XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Sitagliptin-Metformin XR: Formulary list price $0.89 per unit (the source does not state the unit; exact figure $0.8893). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02529114)

Source record
DIN 02529114: Sandoz Sitagliptin-Metformin XR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002051; group id 757; item number 1857; lccId None; manufacturer id SDZ Source form: ER Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.8893; ministry $0.8893 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529114 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101830 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506289 · $0.8893 Janumet XR · DIN 02416794 · $0.8893
Shortage status: resolved shortage (ended December 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02529114
Shortage record checked October 6, 2026

Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · 50 mg & 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Sitagliptin Malate/Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02509415)

Source record
DIN 02509415: Apo-Sitagliptin Malate/Metformin HCl Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id APX Source form: Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02509415 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99871 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446 Janumet · DIN 02333856 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446 Sitagliptin-Metformin · DIN 02529157 · $0.4446 Sitagliptin/Metformin · DIN 02560445 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: active shortage (reported October 8, 2025, last updated February 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509415
Shortage record checked October 6, 2026

Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · 50 mg & 850 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG, SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Sitagliptin Malate/Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02509423)

Source record
DIN 02509423: Apo-Sitagliptin Malate/Metformin HCl Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id APX Source form: Tab; strength: 50mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02509423 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99872 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446 Janumet · DIN 02333864 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446 Sitagliptin-Metformin · DIN 02529165 · $0.4446 Sitagliptin/Metformin · DIN 02560453 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: active shortage (reported September 30, 2025, last updated February 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509423
Shortage record checked October 6, 2026

Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · 50 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-07 · brand APO-SITAGLIPTIN MALATE / METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN MALATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Sitagliptin Malate/Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02509431)

Source record
DIN 02509431: Apo-Sitagliptin Malate/Metformin HCl Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id APX Source form: Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02509431 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99873 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446 Janumet · DIN 02333872 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446 Sitagliptin-Metformin · DIN 02529173 · $0.4446 Sitagliptin/Metformin · DIN 02560461 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: active shortage (reported July 22, 2025, last updated February 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509431
Shortage record checked October 6, 2026

Apo-Sitagliptin-Metformin · DIN 02435772 · 50 mg & 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin-Metformin · DIN 02435772 Manufacturer: Apotex Inc.; listing date 2026-03-31 Health Canada: Marketed since 2026-01-29 · brand APO-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435772)

Source record
DIN 02435772: Apo-Sitagliptin-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id APX Source form: Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435772 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92012 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446 Janumet · DIN 02333856 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446 Sitagliptin-Metformin · DIN 02529157 · $0.4446 Sitagliptin/Metformin · DIN 02560445 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435772
Shortage record checked October 6, 2026

Apo-Sitagliptin-Metformin · DIN 02435780 · 50 mg & 850 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin-Metformin · DIN 02435780 Manufacturer: Apotex Inc.; listing date 2026-03-31 Health Canada: Marketed since 2026-01-29 · brand APO-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435780)

Source record
DIN 02435780: Apo-Sitagliptin-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id APX Source form: Tab; strength: 50mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435780 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92013 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446 Janumet · DIN 02333864 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446 Sitagliptin-Metformin · DIN 02529165 · $0.4446 Sitagliptin/Metformin · DIN 02560453 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435780
Shortage record checked October 6, 2026

Apo-Sitagliptin-Metformin · DIN 02435799 · 50 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Sitagliptin-Metformin · DIN 02435799 Manufacturer: Apotex Inc.; listing date 2026-03-31 Health Canada: Marketed since 2026-01-29 · brand APO-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02435799)

Source record
DIN 02435799: Apo-Sitagliptin-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id APX Source form: Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02435799 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92014 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446 Janumet · DIN 02333872 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446 Sitagliptin-Metformin · DIN 02529173 · $0.4446 Sitagliptin/Metformin · DIN 02560461 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02435799
Shortage record checked October 6, 2026

Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · 50 mg & 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 Manufacturer: Auro Pharma Inc.; listing date 2025-08-29 Health Canada: Marketed since 2025-07-22 · brand AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Sitagliptin HCl and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547805)

Source record
DIN 02547805: Auro-Sitagliptin HCl and Metformin HCl Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id AUR Source form: Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547805 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103673 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446 Janumet · DIN 02333856 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446 Sitagliptin-Metformin · DIN 02529157 · $0.4446 Sitagliptin/Metformin · DIN 02560445 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547805
Shortage record checked October 6, 2026

Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · 50 mg & 850 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 Manufacturer: Auro Pharma Inc.; listing date 2025-08-29 Health Canada: Marketed since 2025-07-22 · brand AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Sitagliptin HCl and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547813)

Source record
DIN 02547813: Auro-Sitagliptin HCl and Metformin HCl Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id AUR Source form: Tab; strength: 50mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547813 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103674 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446 Janumet · DIN 02333864 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446 Sitagliptin-Metformin · DIN 02529165 · $0.4446 Sitagliptin/Metformin · DIN 02560453 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547813
Shortage record checked October 6, 2026

Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · 50 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 Manufacturer: Auro Pharma Inc.; listing date 2025-08-29 Health Canada: Marketed since 2025-07-22 · brand AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Sitagliptin HCl and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02547821)

Source record
DIN 02547821: Auro-Sitagliptin HCl and Metformin HCl Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id AUR Source form: Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02547821 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103675 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446 Janumet · DIN 02333872 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446 Sitagliptin-Metformin · DIN 02529173 · $0.4446 Sitagliptin/Metformin · DIN 02560461 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02547821
Shortage record checked October 6, 2026

Jamp Sitagliptin HCl / Metformin · DIN 02556189 · 50 mg & 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Sitagliptin HCl / Metformin · DIN 02556189 Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29 Health Canada: Marketed since 2025-07-10 · brand JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Sitagliptin HCl / Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556189)

Source record
DIN 02556189: Jamp Sitagliptin HCl / Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556189 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104488 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446 Janumet · DIN 02333856 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446 Sitagliptin-Metformin · DIN 02529157 · $0.4446 Sitagliptin/Metformin · DIN 02560445 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02556189
Shortage record checked October 6, 2026

Jamp Sitagliptin HCl / Metformin · DIN 02556197 · 50 mg & 850 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Sitagliptin HCl / Metformin · DIN 02556197 Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29 Health Canada: Marketed since 2025-07-11 · brand JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 850 MG, SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Sitagliptin HCl / Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556197)

Source record
DIN 02556197: Jamp Sitagliptin HCl / Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556197 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104489 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446 Janumet · DIN 02333864 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446 Sitagliptin-Metformin · DIN 02529165 · $0.4446 Sitagliptin/Metformin · DIN 02560453 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02556197
Shortage record checked October 6, 2026

Jamp Sitagliptin HCl / Metformin · DIN 02556200 · 50 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Sitagliptin HCl / Metformin · DIN 02556200 Manufacturer: Jamp Pharma Corporation; listing date 2025-08-29 Health Canada: Marketed since 2025-07-04 · brand JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Sitagliptin HCl / Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02556200)

Source record
DIN 02556200: Jamp Sitagliptin HCl / Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id JPC Source form: Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556200 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104490 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446 Janumet · DIN 02333872 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446 Sitagliptin-Metformin · DIN 02529173 · $0.4446 Sitagliptin/Metformin · DIN 02560461 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: resolved shortage (ended April 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02556200
Shortage record checked October 6, 2026

Janumet · DIN 02333856 · 50 mg & 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Janumet · DIN 02333856 Manufacturer: Merck Canada Inc.; listing date 2012-02-29 Health Canada: Marketed since 2009-10-08 · brand JANUMET · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333856)

Source record
DIN 02333856: Janumet Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id MEK Source form: Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.8496; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333856 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81954 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446 Sitagliptin-Metformin · DIN 02529157 · $0.4446 Sitagliptin/Metformin · DIN 02560445 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333856
Shortage record checked October 6, 2026

Janumet · DIN 02333872 · 50 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Janumet · DIN 02333872 Manufacturer: Merck Canada Inc.; listing date 2012-02-29 Health Canada: Marketed since 2009-10-08 · brand JANUMET · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 1000 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02333872)

Source record
DIN 02333872: Janumet Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id MEK Source form: Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.8496; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02333872 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81956 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552329 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446 Sitagliptin-Metformin · DIN 02529173 · $0.4446 Sitagliptin/Metformin · DIN 02560461 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: resolved shortage (ended March 17, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02333872
Shortage record checked October 6, 2026

PRZ-Sitagliptin-Metformin · DIN 02552310 · 50 mg & 850 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PRZ-Sitagliptin-Metformin · DIN 02552310 Manufacturer: Pharmaris Canada Inc.; listing date 2026-09-29 Health Canada: Marketed since 2026-06-26 · brand PRZ-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Pharmaris canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PRZ-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02552310)

Source record
DIN 02552310: PRZ-Sitagliptin-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id PRZ Source form: Tab; strength: 50mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02552310 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104099 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446 Janumet · DIN 02333864 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446 Sitagliptin-Metformin · DIN 02529165 · $0.4446 Sitagliptin/Metformin · DIN 02560453 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02552310
Shortage record checked October 6, 2026

PRZ-Sitagliptin-Metformin · DIN 02552329 · 50 mg & 1000 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PRZ-Sitagliptin-Metformin · DIN 02552329 Manufacturer: Pharmaris Canada Inc.; listing date 2026-09-29 Health Canada: Marketed since 2026-06-30 · brand PRZ-SITAGLIPTIN-METFORMIN · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 1000 MG · company Pharmaris canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PRZ-Sitagliptin-Metformin: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02552329)

Source record
DIN 02552329: PRZ-Sitagliptin-Metformin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002039; group id 757; item number 1860; lccId None; manufacturer id PRZ Source form: Tab; strength: 50mg & 1000mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02552329 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104100 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435799 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547821 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556200 · $0.4446 Janumet · DIN 02333872 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540134 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503972 · $0.4446 Sitagliptin-Metformin · DIN 02529173 · $0.4446 Sitagliptin/Metformin · DIN 02560461 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520516 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02552329
Shortage record checked October 6, 2026

Reddy-Sitagliptin and Metformin HCl · DIN 02540118 · 50 mg & 500 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Reddy-Sitagliptin and Metformin HCl · DIN 02540118 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2025-04-30 Health Canada: Marketed since 2023-10-05 · brand REDDY-SITAGLIPTIN AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG · company Dr reddy's laboratories ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Reddy-Sitagliptin and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02540118)

Source record
DIN 02540118: Reddy-Sitagliptin and Metformin HCl Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002037; group id 757; item number 1861; lccId None; manufacturer id DRR Source form: Tab; strength: 50mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540118 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102882 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435772 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547805 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556189 · $0.4446 Janumet · DIN 02333856 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503956 · $0.4446 Sitagliptin-Metformin · DIN 02529157 · $0.4446 Sitagliptin/Metformin · DIN 02560445 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520494 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02540118
Shortage record checked October 6, 2026

Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · 50 mg & 850 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Reddy-Sitagliptin and Metformin HCl · DIN 02540126 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2025-04-30 Health Canada: Marketed since 2023-10-05 · brand REDDY-SITAGLIPTIN AND METFORMIN HYDROCHLORIDE · ATC A10BD07 METFORMIN AND SITAGLIPTIN, A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Dr reddy's laboratories ltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Reddy-Sitagliptin and Metformin HCl: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4446). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02540126)

Source record
DIN 02540126: Reddy-Sitagliptin and Metformin HCl Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id DRR Source form: Tab; strength: 50mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.4446; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02540126 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102883 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446 Janumet · DIN 02333864 · $0.4446 PRZ-Sitagliptin-Metformin · DIN 02552310 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446 Sitagliptin-Metformin · DIN 02529165 · $0.4446 Sitagliptin/Metformin · DIN 02560453 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02540126
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A10B, A10BD): coverage varies; not interchangeable

  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin + metformin (Synjardy): general benefit
  • Linagliptin + metformin (Jentadueto): general benefit
  • Metformin + saxagliptin (Komboglyze): general benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit

12 more in the class list below

Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:20:02 and 6 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS • JANUMET® (sitagliptin/metformin hydrochloride) and JANUMET® XR (sitagliptin/metformin hydrochloride extended-release) are indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on metformin or in patients already being treated with the combination of sitagliptin and metformin. • Add-on combination: JANUMET® and JANUMET® XR are indicated for use as a triple combination therapy in adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: o . sulfonylurea, o . premixed or long/intermediate acting insulin o . pioglitazone when the existing dual therapy with metformin, along with diet and exercise, does not provide adequate glycemic control (see 14 CLINICAL TRIALS). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of JANUMET® and JANUMET® XR in pediatric patients… https://pdf.hres.ca/dpd_pm/00074655.PDF PM date: FEB 20, 2024 Source product: JANUMET; DIN 02333856; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Sitagliptin/Metformin XR · DIN 02506270 Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-16, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02506270

Check this DIN again

Apo-Sitagliptin Malate/Metformin HCl · DIN 02509415 Shortage status: active shortage (reported 2025-10-08, last updated 2026-02-12); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509415

Check this DIN again

Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 Shortage status: active shortage (reported 2025-09-30, last updated 2026-02-12); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509423

Check this DIN again

Apo-Sitagliptin Malate/Metformin HCl · DIN 02509431 Shortage status: active shortage (reported 2025-07-22, last updated 2026-02-12); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509431

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18